Stigningen i sensitivitet fra prækontrastforstærket til postkontrastforstærket MR- scanning for patienter behandlet med Gadovist var 33% i lever- studiet (patient- baseret analyse), og 18% i nyre- studiet (patient - baseret analyse samt læsions- baseret analyse).
The increase of sensitivity from precontrast to combined pre and postcontrast MRI for Gadovist- treated patients was 33% in the liver study (patient-based analysis) and 18% in the kidney study (patient-based analysis as well as lesion-based analysis).